×
0 0 0 0 0.0110294117647058 0.00858455882352932 -0.0220588235294118 -0.0689154411764706
Stockreport

ADMA Biologics granted U.S. Patent for treating respiratory infections [Seeking Alpha]

ADMA BIOLOGICS COMMON (ADMA)  More Company Research Source: Seeking Alpha
Last adma biologics common earnings: 5/14 05:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.admabiologics.com
PDF ADMA Biologics granted U.S. Patent for treating respiratory infectionsUnited States Patent and Trademark Office hasissued ADMA Biologics (NASDAQ:ADMA) U.S. Patent No. 9,969,793 covering methods of treating respiratory infections.The newly issued patent encompasses methods of treating upper and lower respiratory infections, including those caused by Respiratory Syncytial Virus, other viruses, as well as bacteria utilizingRI-002.The term of the patent extends to January 2035.Click to subscribe to real-time analytics on ADMANow read:ImmunoGen: An Extremely Promising ADC Therapeutic Innovator » [Read more]

IMPACT SNAPSHOT EVENT TIME: ADMA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS